Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 40Carcinoma, Non-Small-Cell Lung 22Head and Neck Neoplasms 20Brain Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Glioma 11Lung Neoplasms 8Carcinoma, Squamous Cell 8Breast Neoplasms 8Astrocytoma 8Rectal Neoplasms 7Neoplasms 7Prostatic Neoplasms 6Mucositis 5Esophageal Neoplasms 5Carcinoma 4Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Colorectal Neoplasms 3Xerostomia 2Stomatitis 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Neoplasms, Squamous Cell 2Lymphoma 2Leukemia 2Laryngeal Diseases 2Gliosarcoma 2Adenocarcinoma Of Esophagus 2Adenocarcinoma 2

Interventions

Radiotherapy 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Non-Metastatic Prostate Cancer × Radiotherapy × Clear all
NCT00239291 2009-04-23

Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer

AstraZeneca

Phase 1/2 Completed
42 enrolled
Genitourinary

Non-Metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡